TY  - JOUR
  - Paruch, K.,Dwyer, M. P.,Alvarez, C.,Brown, C.,Chan, T. Y.,Doll, R. J.,Keertikar, K.,Knutson, C.,McKittrick, B.,Rivera, J.,Rossman, R.,Tucker, G.,Fischmann, T.,Hruza, A.,Madison, V.,Nomeir, A. A.,Wang, Y. L.,Kirschmeier, P.,Lees, E.,Parry, D.,Sgambellone, N.,Seghezzi, W.,Schultz, L.,Shanahan, F.,Wiswell, D.,Xu, X. Y.,Zhou, Q. A.,James, R. A.,Paradkar, V. M.,Park, H.,Rokosz, L. R.,Stauffer, T. M.,Guzi, T. J.
  - 2010
  - August
  - Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
  - Validated
  - ()
  - 1
  - 55
  - 204
  - 208204
  - Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation.Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation.
  - 1948-58751948-5875
  - ://WOS:000280919100004://WOS:000280919100004
DA  - 2010/08
ER  - 

@article{V235379083,
   = {Paruch,  K. and Dwyer,  M. P. and Alvarez,  C. and Brown,  C. and Chan,  T. Y. and Doll,  R. J. and Keertikar,  K. and Knutson,  C. and McKittrick,  B. and Rivera,  J. and Rossman,  R. and Tucker,  G. and Fischmann,  T. and Hruza,  A. and Madison,  V. and Nomeir,  A. A. and Wang,  Y. L. and Kirschmeier,  P. and Lees,  E. and Parry,  D. and Sgambellone,  N. and Seghezzi,  W. and Schultz,  L. and Shanahan,  F. and Wiswell,  D. and Xu,  X. Y. and Zhou,  Q. A. and James,  R. A. and Paradkar,  V. M. and Park,  H. and Rokosz,  L. R. and Stauffer,  T. M. and Guzi,  T. J. },
   = {2010},
   = {August},
   = {Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases},
   = {Validated},
   = {()},
   = {1},
   = {55},
  pages = {204--208204},
   = {{Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation.Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation.}},
  issn = {1948-58751948-5875},
   = {://WOS:000280919100004://WOS:000280919100004},
  source = {IRIS}
}